Novo Nordisk patent expiry may broaden access to cheaper weight-loss drugs in India

Novo Nordisk's semaglutide patent has expired in India, and more than 40 local firms are expected to launch over 50 generic brands, which could lower prices while raising concerns about uneven oversight.

India's semaglutide patent held by Novo Nordisk has expired this week, creating space for local manufacturers to introduce generic versions. The topic is receiving attention because semaglutide is used in diabetes and weight-loss treatments and demand has grown after recent product launches. Observers say lower prices could widen access in a price-sensitive market. At the same time, some analysts and doctors warn that enforcement of prescription controls has sometimes been uneven. What is known: - The patent on semaglutide has expired in India, according to the article. - More than 40 Indian firms are expected to launch over 50 generic brands within weeks, the article reports. - The article mentions Sun Pharma, Mankind Pharma, Dr. Reddy's, Zydus, Lupin and Alkem among companies expected to enter with generics. - Semaglutide is a prescription medicine, and the article notes that enforcement and gatekeeping by doctors and pharmacists in India have often been uneven. - Analysts cited in the article expect large price declines, with initial discounts of around 50–60% and projected monthly prices falling from about 11,000 rupees toward lower ranges over time. Summary: The entry of multiple generics is expected to reduce prices and broaden availability beyond a niche urban market. Observers also raise concerns about potential misuse, inconsistent prescribing, and the need for oversight. Multiple brands are likely to appear in the coming weeks, and any regulatory response is undetermined at this time.